{
    "guideline_identifier": "PIIS0923753422047810.txt",
    "cancer_focus": {
        "primary_cancer": "Non-Small Cell Lung Cancer",
        "related_syndrome_or_condition": ""
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "EGFR-mutated",
            "treatment_plans": [
                {
                    "clinical_context": "First-line classical mutations (exon 19 del/L858R)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Osimertinib (preferred) or alternatives: erlotinib, gefitinib, afatinib, dacomitinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "EGFR",
                            "status": "Exon 19 deletion or exon 21 L858R mutation",
                            "testing_guidance": "NGS testing at diagnosis (tissue or liquid biopsy)"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "First-line uncommon non-exon 20 mutations",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Afatinib or osimertinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "EGFR",
                            "status": "Uncommon non-exon 20 mutations",
                            "testing_guidance": "NGS testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III B"
                },
                {
                    "clinical_context": "T790M resistance after first-line TKI",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Osimertinib",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "EGFR",
                            "status": "T790M positive",
                            "testing_guidance": "Re-biopsy or cfDNA testing at progression"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Osimertinib resistance",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum-based chemotherapy or clinical trials",
                    "treatment_line": "Subsequent",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III A"
                },
                {
                    "clinical_context": "Oligoprogression",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Local ablative therapy + continue TKI",
                    "treatment_line": "Any line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV C"
                },
                {
                    "clinical_context": "Elderly/ECOG PS ≥2",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Osimertinib or gefitinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "EGFR",
                            "status": "Positive",
                            "testing_guidance": "Testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "II/III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "ALK-rearranged",
            "treatment_plans": [
                {
                    "clinical_context": "First-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Alectinib, brigatinib, or lorlatinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "ALK",
                            "status": "Rearranged",
                            "testing_guidance": "IHC/FISH or NGS at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Post-crizotinib progression",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Alectinib or brigatinib/ceritinib",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A/III A"
                },
                {
                    "clinical_context": "Post-2nd gen TKI progression",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Lorlatinib",
                    "treatment_line": "Subsequent",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III A"
                },
                {
                    "clinical_context": "Elderly/ECOG PS ≥2",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Alectinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "ALK",
                            "status": "Rearranged",
                            "testing_guidance": "Testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "II/III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "ROS1-rearranged",
            "treatment_plans": [
                {
                    "clinical_context": "First-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Entrectinib (preferred for CNS mets) or crizotinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "ROS1",
                            "status": "Fusion",
                            "testing_guidance": "FISH or RNA-based NGS at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "BRAF V600 mutated",
            "treatment_plans": [
                {
                    "clinical_context": "First-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Dabrafenib + trametinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF",
                            "status": "V600 mutation",
                            "testing_guidance": "NGS testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "RET-fusions",
            "treatment_plans": [
                {
                    "clinical_context": "First-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Selpercatinib or pralsetinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "RET",
                            "status": "Fusion",
                            "testing_guidance": "RNA-based NGS at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "MET exon 14 skipping",
            "treatment_plans": [
                {
                    "clinical_context": "First-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Capmatinib or tepotinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "MET",
                            "status": "Exon 14 skipping mutation",
                            "testing_guidance": "NGS testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "HER2 exon 20 mutations",
            "treatment_plans": [
                {
                    "clinical_context": "Any line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Poziotinib, T-DM1, or trastuzumab deruxtecan",
                    "treatment_line": "Any line",
                    "biomarker_requirements": [
                        {
                            "name": "HER2",
                            "status": "Exon 20 mutation",
                            "testing_guidance": "NGS testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "KRAS G12C mutations",
            "treatment_plans": [
                {
                    "clinical_context": "Post-chemotherapy/immunotherapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Sotorasib or adagrasib",
                    "treatment_line": "Second-line or subsequent",
                    "biomarker_requirements": [
                        {
                            "name": "KRAS",
                            "status": "G12C mutation",
                            "testing_guidance": "NGS testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "I B/III B"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "NTRK fusions",
            "treatment_plans": [
                {
                    "clinical_context": "First-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Larotrectinib or entrectinib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "NTRK",
                            "status": "Fusion",
                            "testing_guidance": "RNA-based NGS at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "EGFR exon 20 insertions",
            "treatment_plans": [
                {
                    "clinical_context": "Post-platinum therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Amivantamab or mobocertinib",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "EGFR",
                            "status": "Exon 20 insertion",
                            "testing_guidance": "NGS testing at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III B/III C"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (AJCC/UICC TNM 8th edition)",
            "risk_group": "Oligometastatic disease (≤5 lesions)",
            "treatment_plans": [
                {
                    "clinical_context": "Synchronous oligometastases",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "TKI + radiotherapy for local consolidation",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II B"
                },
                {
                    "clinical_context": "Oligoprogression on TKI",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Stereotactic radiosurgery (SRS) + continue TKI",
                    "treatment_line": "Any line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Determines selection of targeted therapies and predicts treatment efficacy"
    }
}